Another checkpoint inhibitor, anti-CTLA-4 mAb Ipilimumab, is used in combination with non-engineered allogeneic CIML NKs in head and neck squamous cell carcinoma (HNSCC) patients (Additional file 3: Table S3, row 26). Here, CTLA4 is linked to head and neck squamous cell carcinoma.